B. Braun Medical Inc (Bethlehem, PA) recently launched the Curlin 6000 CMS. The ambulatory electronic infusion system is a comprehensive product that incorporates a convenient PCA pump with both PC and PDA connectivity, and state-of-the-art Clinical Management System (CMS) software. The system is an upgrade on the 4000 series and comes equipped with Information on Demand technology and is capable of delivering intravenous therapy using syringes, bottles, or bags. For added flexibility in hospital settings, the Curlin 6000 CMS offers multiple therapy modes beyond PCA, including TPN with ramp/taper, continuous and intermittent infusions in addition to PCA, and epidural modes. Adding to the features of the Curlin Pain Management System, the Curlin 6000 CMS has built-in safety features, such as integral free-flow protection from upstream occlusion detection and programmable medication limits. It also possesses a larger color screen making it easier to read. The verification and confirmation of dose changes before implementation reduces the risk of programming errors and improves infusion outcomes for patient safety. The system is helpful not only in drug administration, but also in event monitoring. The Curlin 6000 CMS gives health care professionals the ability to retrieve detailed data-rich reports based on the events stored in its log file. The report can indicate events, tampering, or incorrect pump settings. For more information, call 800-854-6851, or visit www.bbraunusa.com.
APP Pharmaceuticals Inc (Schaumburg, IL) recently received FDA approval for its Abbreviated New Drug Application for Colistimethate for Injection, USP, 150 mg. The product is the generic equivalent of JHP Pharmaceuticals? Coly-Mycin M Parenteral. Colistimethate for Injection, USP, 150 mg is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. The product may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible and gram-negative pathogenic bacilli. Colistimethate for Injection, USP, 150 mg, which is suitable for intramuscular or intravenous administration, should be given in 2 to 4 divided doses at dose levels of 2.5 to 5 mg/kg per day for patients with normal renal function, depending on the severity of the infection. The product is AP-rated, bar-coded, and latex-free. For more information, visit www.APPpharma.com, or call 888-386-1300.
American Regent Inc (Shirley, NY) recently announced the availability of Ceftriaxone for Injection, USP. The product is AP-rated to Rocephin (Roche Pharmaceuticals) and is a third-generation cephalosporin antibiotic for intramuscular or intravenous use against both gram-positive and -negative bacteria. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, the product should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. The product is supplied as a sterile crystalline powder in 250-, 500-, 1000-, and 2000-mg glass vials. For more information, call 800-645-1706, or visit www.americanregent.com.
Adolor Corp (Exton, PA) and GlaxoSmithKline (Research Triangle Park, NC) recently received FDA approval for Entereg. The product is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The FDA approved Entereg with a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of the drug outweigh the risks. The REMS will include restricting Entereg to inpatient use only, requiring that hospitals be specially certified, distribution of educational materials to health care professionals, and regular assessments of the effectiveness of the REMS. The recommended dose for Entereg is one 12-mg capsule administered 30 minutes to 5 hours prior to surgery followed by 12 mg twice daily beginning the day after surgery for up to 7 days or not to exceed 15 doses. The product will only be available to hospitals and will come in blister packs that are marked "Hospital Use Only." Entereg is not approved for use in pediatric populations. For more information, visit www.entereg.com, or call 866-4ADOLOR (866-423-6567).
Find it Online
For more Hospital Product News, visit www.PharmacyTimes.com/HospitalProducts